Why IHC Changes What a Histopathology Lab Can Offer
Most labs start with routine H&E sections and a good microscope. But a meaningful share of cases that walk in as a straightforward biopsy turn out to need more than morphology alone can answer — a poorly differentiated tumour of uncertain origin, a lymphoma that needs lineage confirmation, or a breast carcinoma where the oncologist is waiting on ER/PR/HER2 status before planning treatment. Immunohistochemistry (IHC) is what lets a lab answer these questions itself instead of packing the block and sending it across the city.
What IHC Adds Diagnostically
IHC is not a cosmetic add-on to H&E; it changes what a report can actually say.
- Tumour typing and lineage confirmation: Current WHO Classification of Tumours volumes build diagnostic criteria around immunophenotype for many tumour categories, not morphology alone, particularly in lymphomas, soft tissue tumours, and poorly differentiated carcinomas of unknown primary.
- Predictive markers: ER, PR, and HER2 in breast carcinoma directly guide whether a patient is a candidate for endocrine therapy or anti-HER2 therapy, and standardised testing and interpretation criteria have been published by ASCO/CAP guideline committees.
- Prognostic markers: Proliferation markers such as Ki-67 are used to estimate tumour growth fraction and inform prognosis, though the International Ki67 in Breast Cancer Working Group has flagged inter-laboratory scoring variability as an ongoing standardisation challenge.
- Confirming or excluding differentials: A panel can distinguish, for example, a poorly differentiated carcinoma from a lymphoma or melanoma when H&E morphology alone is genuinely ambiguous.
None of this replaces the pathologist's judgement — IHC results are interpreted in the full clinical and morphological context, not read in isolation.
Why In-House IHC Raises Lab Value, Not Just Convenience
When a case is sent out for IHC, the referring lab usually loses the case financially and partly loses it clinically too — the report carries someone else's letterhead, turnaround time stretches to days, and the treating doctor starts routing future cases directly to the reference lab. Bringing IHC in-house keeps the full diagnostic workup, and the associated billing, inside your own workflow.
| Aspect | Send-out IHC | In-house IHC |
|---|---|---|
| Turnaround time | Days, dependent on courier and reference lab queue | Same working week, integrated into your reporting cycle |
| Revenue | Lost to reference lab; referring lab only earns on the base biopsy | Additional per-marker billing on cases already in your possession |
| Clinical relationship | Report identity split across two labs | Single, coherent report under your pathologist's signature |
| Case control | Depends on external lab's block/section quality | You control fixation, processing, and repeat staining if needed |
The practical point for a lab manager is this: IHC does not require new patients. It monetises depth on cases you already receive, which is why it tends to be one of the more predictable ways to grow histopathology revenue.
Common Starter Antibody Panels
Labs new to IHC usually start with markers that cover the bulk of everyday referral needs rather than trying to stock every antibody at once.
- Basic epithelial vs non-epithelial screen: Pan-cytokeratin, vimentin, CD45 (LCA), S100
- Breast panel: ER, PR, HER2, Ki-67
- Lymphoma screening panel: CD3, CD20, CD30, CD15, Ki-67
- GI/hepatobiliary aids: CK7, CK20, CDX2
- Neuroendocrine markers: Synaptophysin, chromogranin
Expansion beyond this depends on your case mix — a lab receiving more skin biopsies will add melanoma markers (SOX10, Melan-A), while one seeing more soft tissue cases will build toward SMA, desmin, and CD34.
Equipment and Workflow Needed
Setting up IHC is a workflow change, not just a purchase.
- Section quality upstream: IHC amplifies pre-analytic problems. A brittle block, poor ribbon formation, or section chatter at microtomy carries through as patchy or uninterpretable staining later.
- Fixation consistency: Formalin fixation duration affects antigen preservation; general laboratory guidance recommends a defined fixation window (commonly cited around 6–72 hours) before processing, since under-fixation and prolonged fixation both distort IHC results.
- Antigen retrieval capability: Formalin fixation cross-links proteins and masks epitopes, so heat-induced or enzymatic antigen retrieval is generally required before antibody application, as described in standard IHC methodology references.
- Staining platform: Manual staining works at low volume but is harder to standardise; an automated or semi-automated IHC stainer improves reproducibility as volumes grow. Labs evaluating equipment can review options under Unimeditrek's histopathology product range.
- Documentation: Batch records, antibody lot numbers, and control outcomes need to be logged per run, not just per day.
Quality Control for IHC
IHC quality control is stricter than routine H&E because a false negative or false positive marker result can directly change treatment decisions.
- Positive and negative controls on every run: Laboratory accreditation frameworks such as CAP's laboratory checklist require appropriate positive and negative tissue controls to accompany each staining run, not periodically.
- Antibody validation before clinical use: New antibody clones or lot changes should be verified against known-positive and known-negative tissue before being used on patient cases.
- Internal and external quality assurance: Participation in an external quality assurance/proficiency testing scheme is part of maintaining and demonstrating IHC competence under laboratory accreditation standards such as ISO 15189, which NABL accreditation in India is based on.
- Avoiding stain carryover: Shared reagent baths or brushes between cases risk cross-contamination; dedicated or properly cleaned staining racks reduce this risk.
- Reagent tracking: An exhausted or expired antibody vial used past validated shelf life is a common, avoidable cause of weak or false-negative staining.
Common Mistakes When Starting IHC
- Running IHC on under-processed or poorly fixed tissue and blaming the antibody when the real fault is upstream
- Skipping negative controls to save reagent, which removes the ability to detect background/non-specific staining
- Choosing a wide antibody menu before staff are trained on interpretation, leading to overcalled or undercalled results
- Not documenting antibody lot changes, making it hard to trace a staining drift back to its cause
- Treating IHC turnaround as flexible when a predictive marker report is directly holding up a treatment decision
Notes for Pathologists
IHC interpretation should always sit alongside morphology and clinical context — a stain result that doesn't fit the H&E picture deserves a second look at both, not an automatic override of one by the other. Building a habit of reviewing control slides before reporting the case slide catches most technical failures early.
Notes for Technicians
Consistency in fixation time, section thickness, and retrieval protocol matters more in IHC than in routine staining because the antibody-antigen reaction is sensitive to small pre-analytic variables. Keeping a simple log of antibody lot, retrieval method, and control outcome per batch makes troubleshooting a failed run far faster.
Notes for Students and Trainees
Learning IHC well means learning to read a negative control as carefully as a positive one — a clean negative control confirms the stain is specific, while background staining on it tells you the run itself is unreliable before you even look at the case.
Safety and Accreditation Notes
Some IHC reagents and antigen retrieval steps involve heated buffers and chemical fixatives that require standard laboratory PPE and ventilation precautions. Labs pursuing or maintaining NABL accreditation should build IHC-specific SOPs, control documentation, and EQAS participation into their existing quality manual rather than treating IHC as a separate, undocumented add-on service.
Key Takeaways
IHC turns a routine biopsy report into a more complete diagnostic answer, and it does so on cases the lab already has in hand — the growth comes from depth of service, not additional patient volume. Getting there safely takes disciplined pre-analytics, defined antibody validation, and consistent control practice, not just a stainer on the bench.
This article is for educational purposes for laboratory and healthcare professionals. It does not replace institutional SOPs, pathologist judgment, manufacturer instructions, validated protocols, or applicable regulatory requirements.